- Home
- VANI vs SERA Comparison
VANI vs SERA Comparison
Compare VANI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VANI | SERA |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 77.2M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VANI | SERA |
|---|---|---|
| Price | $1.16 | $1.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 194.2K | 72.9K |
| Earning Date | 03-27-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.00 | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,000,000.00 | $77,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $1.37 |
| 52 Week High | $1.92 | $4.20 |
Technical Indicators
Market Signals| Indicator | VANI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 32.39 |
| Support Level | $1.17 | $1.80 |
| Resistance Level | $1.27 | $2.00 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 60.22 | 12.77 |
Price Performance
Historical ComparisonAbout VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.